skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Erlotinib in the treatment of advanced pancreatic cancer

Review

(3266) Views  (663) Full article downloads

Authors: Robin K Kelley, Andrew H Ko

Published Date March 2008 Volume 2008:2(1) Pages 83 - 95
DOI: http://dx.doi.org/10.2147/BTT.S1832

Robin K Kelley, Andrew H Ko

University of California, San Francisco, Comprehensive Cancer Center

Abstract: Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in combination have yielded disappointing results, spurring the ongoing search for new agents and combinations in this aggressive malignancy. Inhibitors of the epidermal growth factor receptor (EGFR) have shown promising activity in multiple solid tumors types, and preclinical data support a role for EGFR inhibition in pancreatic cancer. A recent phase III study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) demonstrated a significant survival benefit with the addition of the EGFR tyrosine kinase inhibitor, erlotinib to gemcitabine chemotherapy for the first-line treatment of patients with advanced pancreatic cancer, becoming the first phase III study to demonstrate a survival benefit of combination therapy as well as targeted therapy in this disease. This article reviews the evidence supporting EGFR inhibition and the use of erlotinib in advanced pancreatic cancer as well as future implications of targeted therapy in this challenging malignancy.

Keywords: erlotinib, EGFR, pancreas, pancreatic, Tarceva








Readers of this article also read:

Role of erlotinib in the management of pancreatic cancer
α-L-iduronidase therapy for mucopolysaccharidosis type I
Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Small molecule tyrosine kinase inhibitors in pancreatic cancer
Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
Therapeutic vaccines for malignant brain tumors
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
Current and emerging therapies for the treatment of pancreatic cancer
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed